

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7097152

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
REPRISE BIOPHARMACEUTICS, LLC		12/29/2021
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	SERENITY PHARMACEUTICALS LLC	
<b>Street Address:</b>	105 HAWK COURT	
<b>City:</b>	MILFORD	
<b>State/Country:</b>	PENNSYLVANIA	
<b>Postal Code:</b>	18337	
<b>PROPERTY NUMBERS Total: 7</b>		
<b>Property Type</b>	<b>Number</b>	
Patent Number:	7799761	
Patent Number:	8143225	
Patent Number:	7579321	
Application Number:	12613855	
Application Number:	13599768	
Application Number:	16924843	
Patent Number:	7405203	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(617)523-1231	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	6175701000	
<b>Email:</b>	us-patentbos@goodwinlaw.com, ckomm@goodwinlaw.com, tayube@goodwinlaw.com	
<b>Correspondent Name:</b>	GOODWIN PROCTER LLP	
<b>Address Line 1:</b>	100 NORTHERN AVENUE	
<b>Address Line 2:</b>	IP DOCKETING DEPT., 7TH FLOOR	
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210	
<b>ATTORNEY DOCKET NUMBER:</b>	SER-001,C1-C5,D1	
<b>NAME OF SUBMITTER:</b>	CRYSTAL A. KOMM	
<b>SIGNATURE:</b>	/Crystal A. Komm/	

<b>DATE SIGNED:</b>	12/29/2021
<b>Total Attachments: 3</b> source=SER-001 Patent Assignment - Reprise to Serenity#page1.tif source=SER-001 Patent Assignment - Reprise to Serenity#page2.tif source=SER-001 Patent Assignment - Reprise to Serenity#page3.tif	

## **ACKNOWLEDGEMENT AND ASSIGNMENT**

WHEREAS, REPRISE BIOPHARMACEUTICS, LLC (hereinafter "ASSIGNOR"), a limited liability company organized and existing under the laws of New York, and having a usual place of business at 120 North Main Street, Suite 400, New City, NY 10956 owns an undivided interest in the invention(s) as described and set forth in the patents and patent applications listed on Schedule A attached hereto (hereinafter, the "Scheduled Patents and Patent Applications"); and

WHEREAS, Serenity Pharmaceuticals LLC (hereinafter "ASSIGNEE"), a limited liability company organized and existing under the laws of Delaware, and having a usual place of business at 105 Hawk Court, Milford, PA 18337, desires to acquire the entirety of ASSIGNOR's undivided interest in and to said invention(s) and said Scheduled Patents and Patent Applications and in any patents which may be granted therefrom and/or claim priority thereto; and

WHEREAS, the parties acknowledge and agree that ASSIGNEE granted an increased equity position in ASSIGNEE's company to ASSIGNOR in exchange for the assignment of the Scheduled Patents and Patent Applications to the ASSIGNEE (the "Prior Consideration");

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of the Prior Consideration and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR has sold, assigned and transferred, and by these presents does hereby sell, assign, and transfer unto ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR's entire and undivided right, title and interest in the United States of America, its territories, and all foreign countries throughout the world to the Scheduled Patents and Patent Applications and the invention(s) disclosed therein, as well as any patents that may issue therefrom or any patents or patent applications that may claim priority thereto under United States or foreign law, or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions thereof, said invention(s), Scheduled Patents and Patent Applications, as well as any patents that may issue therefrom or any patents or patent applications that may claim priority thereto to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby conveys all of its rights in the Scheduled Patents and Patent Applications arising under or pursuant to any and all United States or foreign laws and international agreements, treaties or laws relating to the protection of industrial property, including but not limited to any cause(s) of action and damages accruing prior to this assignment. ASSIGNOR hereby acknowledges that this acknowledgement and assignment, being of its entire right, title and interest in and to said invention(s) and Scheduled Patents and Patent Applications and in any patents which may be granted therefrom and/or claim priority thereto, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all patents to ASSIGNEE in its own name as assignee of ASSIGNOR's entire right, title and interest therein;

AND, ASSIGNOR hereby further agrees for itself and its executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully for ASSIGNEE the aforesaid invention(s) and the Scheduled Patents and Patent Applications and any patents which may be granted therefrom and/or claim priority thereto to said ASSIGNEE, its successors, assigns, and legal representatives, but at ASSIGNEE's own expense, including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications;

Assignment  
Page 2 of 3

AND, ASSIGNOR hereby authorizes and requests the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue Letters Patent as shall be granted upon said Scheduled Patent Applications, or applications based thereon or claiming priority thereto, to said ASSIGNEE, its successors, assigns, or legal representatives.

IN TESTIMONY WHEREOF, ASSIGNOR and ASSIGNEE have caused their respective duly authorized representatives to execute this Assignment.

By: REPRISE BIOPHARMACEUTICS LLC

DocuSigned by:

*Seymour Fein*

D412359F7C67448...

Seymour Fein, MD

Managing Partner

Date: 12/29/2021

Accepted by: SERENITY PHARMACEUTICALS LLC

DocuSigned by:

*Samuel Herschkowitz*

E4CFCA44C495488...

Samuel Herschkowitz, MD

Chief Executive Officer

Date: 12/29/2021

SCHEDULE A

<b>Docket Number</b>	<b>Country</b>	<b>Application Status</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Patent Number</b>	<b>Issue Date</b>
SER-001B/AU	Australia	Granted	2003287591	10-Nov-2003	2003287591	03-Dec-2009
SER-001B/CA	Canada	Granted	2545194	10-Nov-2003	2545194	21-Oct-2014
SER-001B/EP	Europe	Pending	03781836.6	10-Nov-2003		
SER-001B/EPD1	Europe	Pending	11000468.6	10-Nov-2003		
SER-001B/EPD2	Europe	Pending	11000467.8	10-Nov-2003		
SER-001B/EPD3	Europe	Pending	11000466.0	10-Nov-2003		
SER-001B/EPD4	Europe	Pending	11000465.2	10-Nov-2003		
SER-001B/EPD5	Europe	Pending	11000464.5	10-Nov-2003		
SER-001B/HK	Hong Kong	Pending	07101883.1	10-Nov-2003		
SER-001B/JP	Japan	Granted	2005-510644	10-Nov-2003	5596252	15-Aug-2014
SER-001B/JPD2	Japan	Granted	2014-133867	10-Nov-2003	6341777	25-May-2018
SER-001B/JPD3	Japan	Granted	2015-206674	10-Nov-2003	6523132	10-May-2019
SER-001B/JPD4	Japan	Granted	2016-201976	10-Nov-2003	6636893	27-Dec-2019
SER-001US	United States	Granted	10/706100	12-Nov-2003	7799761	21-Sep-2010
SER-001USC1	United States	Granted	12/173072	15-Jul-2008	8143225	27-Mar-2012
SER-001USC2	United States	Expired	12/173074	15-Jul-2008	7579321	25-Aug-2009
SER-001USC3	United States	Abandoned	12/613855	06-Nov-2009		
SER-001USC4	United States	Abandoned	13/599768	30-Aug-2012		
SER-001USC5	United States	Pending	16/924843	09-Jul-2020		
SER-001USD1	United States	Expired	11/744615	04-May-2007	7405203	29-Jul-2008
SER-001A/WO	PCT	Nationalized	US03/14463	06-May-2003		
SER-001B/WO	PCT	Nationalized	US03/35662	10-Nov-2003		